Paolo Lopedote

<i>MYD88</i> L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study

Andrés J.M. Ferreri, Teresa Calimeri, Paolo Lopedote et al. · British Journal of Haematology · 2021 · 84 citations · Full text

Immunodeficiencies, Immunology, Pathology +22

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

Andrés J.M. Ferreri, Teresa Calimeri, Gian Marco Conte et al. · Blood · 2019 · 50 citations · Full text

Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial

Andrés J.M. Ferreri, Teresa Calimeri, Maurilio Ponzoni et al. · Blood Advances · 2020 · 35 citations · Full text

Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis

Stephen D. Smith, Paolo Lopedote, Yazeed Samara et al. · Clinical Lymphoma Myeloma & Leukemia · 2020 · 25 citations

Lymphoid Neoplasia, Multicenter Post-marketing Analysis, Medicine +9

Risk stratification and management algorithms for patients with diffuse large B-cell lymphoma and CNS involvement

Teresa Calimeri, Paolo Lopedote, Andrés J.M. Ferreri · Annals of Lymphoma · 2019 · 11 citations · Full text